Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Fuereder

Showing results (11-20 of 73) with videos related to

Pageof 8
Sort By:
Arthritis and Rheumatism|May 28, 2010
Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritisDaniel Cejka, Silvia Hayer, Birgit Niederreiter, et al.
Scientific Reports|August 12, 2016
Risk factors for Clostridium difficile infection in hemato-oncological patients: A case control study in 144 patientsThorsten Fuereder, Danjel Koni, Andreas Gleiss, et al.
Anticancer Research|February 5, 2009
mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivoDaniel Cejka, Matthias Preusser, Thorsten Fuereder, et al.
Head & Neck|June 22, 2023
Effect of mannitol-based reduced-volume hydration on kidney function in concomitant cisplatin-based chemoradiation for head-and-neck squamous cell carcinomaChristopher Paschen, Matthias Moll, Gabriela Altorjai, et al.
Cancers|November 18, 2020
Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck CancersHossein Taghizadeh, Robert M Mader, Leonhard Müllauer, et al.
Scientific Reports|September 7, 2016
Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancerDoris Posch, Hannah Fuchs, Gabriela Kornek, et al.
Medical Oncology (Northwood, London, England)|February 8, 2018
Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancerHannah Fuchs, Johannes Pammer, Christoph Minichsdorfer, et al.
Plos One|April 24, 2014
Circulating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker studyThorsten Fuereder, Volker Wacheck, Sabine Strommer, et al.
Cancer Biology & Therapy|August 19, 2008
Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivoDaniel Cejka, Matthias Preusser, Adelheid Woehrer, et al.
Cancer Biology & Therapy|April 21, 2010
Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivoAgnes Jaeger-Lansky, Daniel Cejka, Liu Ying, et al.
Pageof 8

Showing results (11-20 of 73) with videos related to

Sort By:
Pageof 8
Arthritis and Rheumatism|May 28, 2010
Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritisDaniel Cejka, Silvia Hayer, Birgit Niederreiter, et al.
Scientific Reports|August 12, 2016
Risk factors for Clostridium difficile infection in hemato-oncological patients: A case control study in 144 patientsThorsten Fuereder, Danjel Koni, Andreas Gleiss, et al.
Anticancer Research|February 5, 2009
mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivoDaniel Cejka, Matthias Preusser, Thorsten Fuereder, et al.
Head & Neck|June 22, 2023
Effect of mannitol-based reduced-volume hydration on kidney function in concomitant cisplatin-based chemoradiation for head-and-neck squamous cell carcinomaChristopher Paschen, Matthias Moll, Gabriela Altorjai, et al.
Cancers|November 18, 2020
Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck CancersHossein Taghizadeh, Robert M Mader, Leonhard Müllauer, et al.
Scientific Reports|September 7, 2016
Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancerDoris Posch, Hannah Fuchs, Gabriela Kornek, et al.
Medical Oncology (Northwood, London, England)|February 8, 2018
Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancerHannah Fuchs, Johannes Pammer, Christoph Minichsdorfer, et al.
Plos One|April 24, 2014
Circulating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker studyThorsten Fuereder, Volker Wacheck, Sabine Strommer, et al.
Cancer Biology & Therapy|August 19, 2008
Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivoDaniel Cejka, Matthias Preusser, Adelheid Woehrer, et al.
Cancer Biology & Therapy|April 21, 2010
Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivoAgnes Jaeger-Lansky, Daniel Cejka, Liu Ying, et al.
Pageof 8